Tabor Jr, Regies C.
HRN: 26-39-79 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/10/2025
MUPIROCIN 2%, 15G (TUBE)
03/10/2025
03/16/2025
TOPICAL
2%
BID
IV Site Inflammation
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes